Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk and Causation

From General Health Information to Occupational Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical risks, emphasizing broad preventive measures and lifestyle factors. Within this framework, discussions of pharmaceutical safety have typically focused on therapeutic benefits and common adverse effects, framed for a general audience. However, as scientific inquiry deepens, the need arises to pivot from this generalized context toward more specific exposure scenarios, particularly those encountered in occupational settings. In the domain of mass production, where workers may handle or be exposed to pharmaceutical compounds during manufacturing, the focus shifts from patient-oriented risk communication to industrial hygiene and exposure assessment. This transition requires examining how substances like Avelumab, a therapeutic agent, might present distinct risk profiles when encountered repeatedly in a workplace environment rather than in controlled clinical administration. The concern here is not about disease mechanisms but about the potential for occupational exposure to contribute to long-term health outcomes, such as Merkel Cell Carcinoma risk, as suggested by emerging studies. By moving from general health literacy to targeted occupational exposure analysis, we can better address the unique vulnerabilities of production workers and inform evidence-based safety protocols.

Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma

Avelumab, a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1), functions as an immune checkpoint inhibitor and is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC) (https://pubmed.ncbi.nlm.nih.gov/29799096/). MCC is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis, associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The approval of avelumab for metastatic MCC was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). This positions avelumab as the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The clinical presentation of MCC typically involves a rapidly growing, painless, firm, dome-shaped nodule on sun-exposed skin, often on the head, neck, or extremities. Diagnosis is confirmed through histopathological examination and immunohistochemistry, with markers such as cytokeratin-20 and neuroendocrine markers like chromogranin and synaptophysin. Given its aggressive nature, early detection and treatment are critical, yet the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is rising, and despite advances in systemic therapy, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors (ICIs) progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Immune-Related Adverse Events and Treatment Resistance

Avelumab's pharmacology involves blocking PD-L1, thereby preventing the inhibition of T-cell activity and enhancing the immune response against tumor cells. However, this mechanism can also lead to immune-related adverse events (irAEs), which are a known risk with ICIs. In MCC, the use of avelumab has been associated with response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). Nevertheless, a significant proportion of patients do not respond or develop irAEs due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). These adverse effects can range from mild to severe and may involve various organ systems, including the skin, gastrointestinal tract, liver, and endocrine glands. Mechanistic pathways linking avelumab to MCC are primarily centered on its role as an immune checkpoint inhibitor. By blocking PD-L1, avelumab enhances T-cell activity, which can lead to tumor regression in responsive patients. However, this immune activation can also trigger irAEs, which are a consequence of the drug's mechanism of action. In the context of MCC, the tumor microenvironment may exhibit down-regulation of MHC complexes or induction of anti-inflammatory cytokines, contributing to resistance or adverse events (https://pubmed.ncbi.nlm.nih.gov/34445385/). Additionally, the Merkel cell polyomavirus, present in approximately 80% of MCC cases, may influence the immune response and the efficacy of avelumab (https://pubmed.ncbi.nlm.nih.gov/34445385/). The remaining 20% of cases are induced by UV light, leading to mutations that may also affect treatment outcomes (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Causation and Risk: What the Evidence Shows

Regarding the adequacy of warnings for avelumab and MCC, the drug's prescribing information includes warnings about immune-mediated adverse reactions, which are standard for ICIs. However, the specific risk of developing MCC as a consequence of avelumab treatment is not a recognized adverse effect; rather, avelumab is used to treat MCC. The evidence indicates that avelumab is an approved therapy for metastatic MCC, and its use is associated with clinical benefits, including durable responses (https://pubmed.ncbi.nlm.nih.gov/29799096/). Therefore, the risk narrative focuses on the potential for irAEs and treatment resistance rather than causation of MCC. Causation-related considerations for affected patients involve understanding that avelumab is a treatment for MCC, not a cause. Patients who experience progression on avelumab may be considered for alternative therapies, such as combined ipilimumab and nivolumab, which have shown activity in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In a multicenter study, three out of five patients with avelumab-refractory MCC responded to combined ipilimumab and nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). This highlights the importance of monitoring for treatment response and managing adverse events. The timeline between exposure to avelumab and documented harm typically involves the development of irAEs, which can occur weeks to months after initiation of therapy. In the JAVELIN Merkel 200 trial, responses were observed in approximately one-third of patients, indicating that the drug can be effective, but also that a subset of patients may experience progression or adverse events (https://pubmed.ncbi.nlm.nih.gov/29799096/). The risk of irAEs is a known concern with ICIs, and patients should be monitored closely for signs of immune-related toxicity. In summary, avelumab is an established treatment for metastatic MCC, with evidence supporting its efficacy in a subset of patients. The risk of adverse events, including irAEs and treatment resistance, is inherent to its mechanism of action. Causation of MCC by avelumab is not supported by the evidence; rather, the drug is used to manage the disease. Patients and clinicians should be aware of the potential for irAEs and the need for alternative therapies in refractory cases.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

No, avelumab is used to treat Merkel cell carcinoma (MCC), not cause it. The evidence shows avelumab is an approved therapy for metastatic MCC and is associated with clinical benefits, including durable responses (https://pubmed.ncbi.nlm.nih.gov/29799096/). The risk of developing MCC from avelumab is not supported by scientific literature.

What are the main risks associated with avelumab treatment?

The main risks are immune-related adverse events (irAEs) and treatment resistance. irAEs can affect various organ systems and occur due to the drug's mechanism of blocking PD-L1, which enhances T-cell activity (https://pubmed.ncbi.nlm.nih.gov/34445385/). Approximately 50% of patients with advanced MCC may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.